Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024
Hyperfine (Nasdaq: HYPR), developer of the Swoop® system—the first FDA-cleared portable magnetic resonance brain imaging system—has scheduled its Q3 2024 financial results announcement for November 12, 2024. Management will host a conference call at 1:30 PM PT/4:30 PM ET. The webcast will be accessible through the company's investor relations webpage, with advance registration recommended.
Hyperfine (Nasdaq: HYPR), sviluppatore del sistema Swoop®—il primo sistema di imaging cerebrale a risonanza magnetica portatile approvato dalla FDA—ha programmato l'annuncio dei suoi risultati finanziari del Q3 2024 per il 12 novembre 2024. La direzione ospiterà una teleconferenza alle 13:30 PT/16:30 ET. La trasmissione in streaming sarà accessibile attraverso la pagina web delle relazioni con gli investitori dell'azienda, ed è consigliata la registrazione anticipata.
Hyperfine (Nasdaq: HYPR), desarrollador del sistema Swoop®—el primer sistema portátil de imagen por resonancia magnética cerebral aprobado por la FDA—ha programado el anuncio de sus resultados financieros del Q3 2024 para el 12 de noviembre de 2024. La dirección realizará una llamada de conferencia a la 1:30 PM PT/4:30 PM ET. La transmisión web estará disponible a través de la página de relaciones con inversores de la compañía, y se recomienda la inscripción anticipada.
Hyperfine (Nasdaq: HYPR), 미국 FDA의 승인을 받은 최초의 휴대용 자기 공명 뇌 영상 시스템인 Swoop® 시스템의 개발 업체로, 2024년 3분기 재무 결과 발표를 2024년 11월 12일로 예정했습니다. 경영진은 태평양 표준시로 오후 1시 30분 / 동부 표준시로 오후 4시 30분에 전화 회의를 진행할 예정입니다. 웹세미나는 회사의 투자자 관계 웹 페이지를 통해 접근할 수 있으며, 사전 등록이 권장됩니다.
Hyperfine (Nasdaq: HYPR), développeur du système Swoop®—le premier système d'imagerie par résonance magnétique cérébrale portable approuvé par la FDA—a prévu l'annonce de ses résultats financiers du T3 2024 pour le 12 novembre 2024. La direction animera une conférence téléphonique à 13h30 PT/16h30 ET. Le webinaire sera accessible via la page de relations investisseurs de l'entreprise, avec une inscription préalable recommandée.
Hyperfine (Nasdaq: HYPR), Entwickler des Swoop®-Systems—des ersten von der FDA zugelassenen tragbaren Magnetresonanztomographie-Systems für das Gehirn—hat die Bekanntgabe seiner Q3 2024 Finanzdaten für den 12. November 2024 angesetzt. Das Management wird um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten. Der Webcast wird über die Investor-Relations-Webseite des Unternehmens zugänglich sein, und eine vorherige Registrierung wird empfohlen.
- None.
- None.
A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call.
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.
The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc..
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024379840/en/
Investor Contact
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
Source: Hyperfine, Inc.
FAQ
When will Hyperfine (HYPR) release Q3 2024 earnings?
What time is Hyperfine's (HYPR) Q3 2024 earnings call?